Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
Patent 5202110 Issued on April 13, 1993. Estimated Expiration Date: 
January 22, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 22, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesPhysically modified beclomethasone dipropionate suitable for use in aerosols Patent #: 4810488 InventorsAssigneeApplicationNo. 824030 filed on 01/22/1992US Classes:424/45, Organic pressurized fluid424/43EFFERVESCENT OR PRESSURIZED FLUID CONTAININGExaminersPrimary: Raymond, Richard L.Assistant: Kumar, Shailendra Attorney, Agent or FirmForeign Patent References
International ClassA61L 009/04AbstractBeclomethasone diproprionate (BDP) forms a clathrate with HCFC-123, dimethyl ether (DME) and HCFC-141b which are less harmful propellants than the CFC propellants currently used in metered dose inhalers (MDIs). The clathrate can be remicronized and suspended for use in an MDI. BDP also is completely dissolved by DME based propellant blends and certain HCFC 123 propellant blends. Using propellant blends which completely dissolve BDP will assure more efficient dosing with an MDI. | |
